Sign In
Buy ORGO
Organogenesis Holdings . Class A Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.290 |
| EPS actual | -$0.370 |
| EPS Surprise | -27.59% |
| Revenue estimate | 43.262M |
| Revenue actual | 36.25M |
| Revenue Surprise | -16.21% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.215 |
| EPS actual | $0.310 |
| EPS Surprise | 44.19% |
| Revenue estimate | 172.65M |
| Revenue actual | 225.071M |
| Revenue Surprise | 30.36% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.210 |
| EPS actual | $0.180 |
| EPS Surprise | -14.29% |
| Revenue estimate | 172.675M |
| Revenue actual | 150.864M |
| Revenue Surprise | -12.63% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.0700 |
| EPS actual | -$0.0900 |
| EPS Surprise | -228.57% |
| Revenue estimate | 134.1M |
| Revenue actual | 101.005M |
| Revenue Surprise | -24.68% |
Last 4 Quarters for Organogenesis Holdings . Class A
Below you can see how ORGO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $4.52 |
| EPS estimate | $0.0700 |
| EPS actual | -$0.0900 |
| EPS surprise | -228.57% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $4.51 |
| Aug 04, 2025 | $4.60 |
| Aug 05, 2025 | $4.53 |
| Aug 06, 2025 | $4.50 |
| Aug 07, 2025 | $4.52 |
| Aug 08, 2025 | $4.56 |
| Aug 11, 2025 | $4.62 |
| Aug 12, 2025 | $4.89 |
| Aug 13, 2025 | $4.91 |
| 4 days before | 0.222% |
| 4 days after | 8.63% |
| On release day | 0.774% |
| Change in period | 8.87% |
| Release date | Nov 06, 2025 |
| Price on release | $3.89 |
| EPS estimate | $0.210 |
| EPS actual | $0.180 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $4.25 |
| Nov 03, 2025 | $4.00 |
| Nov 04, 2025 | $3.88 |
| Nov 05, 2025 | $3.97 |
| Nov 06, 2025 | $3.89 |
| Nov 07, 2025 | $5.63 |
| Nov 10, 2025 | $6.54 |
| Nov 11, 2025 | $6.50 |
| Nov 12, 2025 | $6.48 |
| 4 days before | -8.47% |
| 4 days after | 66.58% |
| On release day | 44.73% |
| Change in period | 52.47% |
| Release date | Feb 26, 2026 |
| Price on release | $3.70 |
| EPS estimate | $0.215 |
| EPS actual | $0.310 |
| EPS surprise | 44.19% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $3.99 |
| Feb 23, 2026 | $3.92 |
| Feb 24, 2026 | $4.03 |
| Feb 25, 2026 | $4.11 |
| Feb 26, 2026 | $3.70 |
| Feb 27, 2026 | $3.21 |
| Mar 02, 2026 | $3.00 |
| Mar 03, 2026 | $2.87 |
| Mar 04, 2026 | $2.87 |
| 4 days before | -7.27% |
| 4 days after | -22.43% |
| On release day | -13.24% |
| Change in period | -28.07% |
| Release date | May 07, 2026 |
| Price on release | $2.51 |
| EPS estimate | -$0.290 |
| EPS actual | -$0.370 |
| EPS surprise | -27.59% |
| Date | Price |
|---|---|
| May 01, 2026 | $2.57 |
| May 04, 2026 | $2.56 |
| May 05, 2026 | $2.59 |
| May 06, 2026 | $2.56 |
| May 07, 2026 | $2.51 |
| May 08, 2026 | $2.37 |
| May 11, 2026 | $2.33 |
| May 12, 2026 | $2.41 |
| May 13, 2026 | $2.70 |
| 4 days before | -2.30% |
| 4 days after | 7.53% |
| On release day | -5.62% |
| Change in period | 5.06% |
Organogenesis Holdings . Class A Earnings Call Transcript Summary of Q1 2026
Organogenesis reported a difficult Q1 2026 with net product revenue of $36.3M, down 58% year-over-year, driven by a 63% decline in Advanced Wound Care sales. Management attributes the steep decline to market disruption following CMS commentary on December 30 regarding discarded/wastage policies and the withdrawal of LCD coverage policies, plus implementation and claims-processing issues (WISeR and a MAC). Despite the revenue drop, management says unit volumes outperformed the market and they believe they gained share. The company completed a BLA submission for ReNu (symptomatic knee osteoarthritis) and announced positive RCT results for PuraPly AM in diabetic foot ulcers, strengthening their clinical evidence base. Gross margin was pressured by inventory write-downs and regulatory-related costs; GAAP net loss was $53.2M. Cash was $92.1M at quarter end with no debt and a $75M revolver available. Management completed a restructuring (facility closure and 88 headcount reduction) expected to save ~$14M annually and updated full-year 2026 net revenue guidance to $270M–$310M (a 45%–52% decline vs. prior year) with sequential improvement expected through the year and a return to more normalized profitability by Q4. Operating expense reductions (excluding COGS) are expected to be ~25% y/y for 2026, with >30% reduction in H2, including ~$7M of restructuring savings in Q3–Q4.
